The year started strong for Jazz Pharmaceuticals (JAZZ) with a Q4 2024 revenue beat and the company guiding 2025 revenues just slightly below the analyst consensus. However, the stock is down 22% ...

Forbes contributors publish independent expert analyses and insights. Scott Hutcheson teaches leadership at Purdue University. In the fast-moving, disruption-heavy environment most of us are currently ...